相关实验视频

Updated: May 5, 2026

On-Chip Endothelial Inflammatory Phenotyping

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 22, 2012

抵抗素是人类动脉样硬化炎症的炎症标志物

Muredach P Reilly¹, Michael Lehrke, Megan L Wolfe

¹Division of Cardiology, Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pa, USA. muredach@spirit.gcrc.upenn.edu.

|February 16, 2005

概括

血抵抗素水平与炎症标志物相关,并预测人类的冠状动脉化. 这表明抵抗素可能会连接代谢信号,炎症和动脉样硬化,独立于C反应蛋白.

科学领域:

内分泌学在内分泌学.
心血管医学心血管医学
免疫学免疫学免疫学

背景情况:

血蛋白质抵抗素 (resistin) 与胰岛素抵抗有关.
在肥胖和胰岛素抵抗性个体中观察到较高的抵抗水平.
巨细胞是人类抵抗素的主要来源,与动物不同,脂肪细胞是主要的生产者.

研究的目的:

为了研究血抵抗素水平和代谢/炎症标志物之间的关联.
为了确定抵抗素水平是否预测无症状患者的冠状动脉化 (CAC).

主要方法:

从冠状动脉样硬化遗传风险研究中分析了879名无症状受试者的血抵抗水平.
评估与炎症标记物的关联 (例如,可溶性瘤亡因子-α受体-2,白素-6,脂蛋白相关脂酶A2) 和胰岛素耐药性措施.
与冠状动脉化 (CAC) 的相关性使用顺序回归,调整各种风险因素和C反应蛋白 (CRP).

主要成果:

血抗原水平与炎症标志物有积极关联,但在多变量分析中与胰岛素耐药性没有直接关联.
在调整人口统计和风险因素后,抵抗剂水平与冠状动脉化 (CAC) 的增加显著相关.
在代谢综合征患者中,抵抗素水平独立预测了CAC,表现优于C反应蛋白 (CRP).

结论:

血抗原水平与炎症有关,并预测人类的冠状动脉样硬化,独立于CRP.
耐药素可以作为一种新的生物标志物,连接代谢障碍,炎症和动脉样硬化的发展.
需要进一步的研究,以充分阐明抵抗素在临床心血管疾病中的作用.

更多相关视频

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

相关概念视频

Inflammation

Inflammation

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...